How Statins Quietly Disrupt Muscle Cells
The biology behind muscle pain: calcium chaos, microscopic damage, and the overlooked mechanism that explains how statins can quietly affect muscle from the inside out.
I just read a bizarre paper about statins.
My first reaction was pure wonder: “This is fascinating—biology is unbelievable!”
My second reaction, a heartbeat later, was more practical: “How do I get anyone to care about this—doctor or layperson?”
The paper is titled (brace yourself): “Cryo-electron Microscopy Reveals Sequential Binding and Activation of Ryanodine Receptors by Statin Triplets.”
I promise I’ll explain exactly what that means in a moment.
Don’t leave!
But first, another promise: this won’t be a detour into esoteric science for its own sake.
This story builds toward something important, practical, and broadly relevant—about how medicine works today, what its blind spots are, and where it’s heading.
We’ll get there through a few concrete examples with the goal of glimpsing the arc of medical progress.
For now, we start with this paper…
Statins, Muscle Pain, and an Old Mystery
Here’s the basic setup. Statins are among the most prescribed (and profitable) drugs in the world.
Their primary mechanism is relatively straightforward: they inhibit a key enzyme involved in cholesterol synthesis.
Problem: a subset of people experience muscle symptoms, often described as pain or aching—what clinicians call “myalgias.”
I’ve experienced this myself when I tried Lipitor (atorvastatin) and Crestor (rosuvastatin).
A small subset of people can even develop “rhabdomyolysis,” a dangerous condition involving severe muscle breakdown.
And despite decades of use, there’s been a stubborn question hanging in the air:
Why do statins cause muscle problems in some people?
Yes, there’s debate about “nocebo” effects and misattribution (and we can talk about that another time). But at the level of biology, it’s well established that statins can harm muscle. The mechanism has never been fully satisfying.
Enter: Ryanodine Receptors (RYRs)
To understand the new finding, you need one more piece of anatomy-meets-physics.
Muscle contraction isn’t a simple “muscle squeezes.” Your muscles aren’t rubber bands draped over bones. Each contraction is electrical signaling translated into exquisitely timed calcium choreography.
Inside muscle cells are ion channels called ryanodine receptors (RYRs).
In skeletal muscle, the dominant form—RYR1—releases calcium from an internal storage depot known as the sarcoplasmic reticulum.
That calcium release is what makes contraction possible in the first place.
A quick appreciation moment, because the system is absurdly elegant.
*That said, if you want you can skip down to the next section, “What the Paper Found (and Why it’s Weird),” you won’t lose any critical context.
When you contract a muscle, a nerve impulse propagates along the muscle cell membrane and then dives into deep invaginations called T-tubules.
There, voltage-sensitive proteins (Cav1.1 / dihydropyridine receptors) undergo a conformational change that is mechanically coupled to RYR1, triggering a rapid release of calcium into the cytoplasm.
That calcium binds specifically to troponin C, which shifts tropomyosin out of the way, exposing binding sites on actin.
Myosin heads can then bind actin and undergo cross-bridge cycling: ATP binding causes detachment, ATP hydrolysis re-cocks the myosin head, and phosphate release drives the power stroke that pulls actin and myosin past one another.
That microscopic walking—powered by ATP—is a “muscle contraction.”
Then, calcium then has to be actively pumped back into the sarcoplasmic reticulum by SERCA pumps, allowing the system to reset and fire again—over and over, every rep, every step, and (with some mechanistic differences) every heartbeat.
So yes: every time you curl a dumbbell, this is unfolding across countless muscle fibers in your body, in parallel, with astonishing precision!
What the Paper Found (and Why it’s Weird)
Now back to the headline: cryo-electron microscopy (cryo-EM) is a cutting-edge imaging method that lets researchers visualize molecular structures at very high resolution to “see” how drugs interact with proteins.
Using single-particle cryo-EM, the authors looked at atorvastatin binding to RYR1, a ryanodine receptor found in skeletal muscle.
And what they saw was… unusual.
This wasn’t a simple “drug docks into a pocket” situation.
The binding involved multiple statin molecules interacting not only with the receptor, but with each other—forming a kind of three-drug interface (“triplets” — see, the title is starting to make sense) that stabilized the interaction and altered channel behavior.
In other words, the drug wasn’t just binding the protein. The drug molecules were binding each other in a way that changed how they bound the protein.
That’s rare. And it has consequences: altered calcium signaling can translate into altered muscle function—and potentially muscle symptoms.
A and B show the chemical structure of atorvastatin, indicating the various constituent parts. C shows a side-view of RyR1 bound to atorvastatin triplets.
Why Any of This Matters
So why am I telling you this?
Because this is a vivid example of the kind of technological leap medicine needs if we want to move beyond trial-and-error pharmacology.
For much of modern history, drug discovery has looked like this:
Find a target or a biomarker → give a compound → see what happens → hope the off-target effects aren’t too bad.
The problem is that off-target effects are often hard to predict, hard to explain, and hard to troubleshoot—especially when the mechanism is structurally complex or wasn’t even visible to us.
Historically, no one could have seen interactions like this in real time. Now we can—and increasingly so.
And the stakes aren’t academic.
When we don’t understand off-target effects, people can get seriously hurt. One sobering example: cerivastatin, approved in 1997, was withdrawn in 2001 after 52 fatal cases of rhabdomyolysis.
This is not just cool imaging. It’s life and death.
Where We Go From Here
This is the moment where we zoom out and get deeply practical.
For StayCurious Metabolism Premium members, next I’ll walk through:
The real-world tradeoffs of statin therapy
What I would consider instead (and why)
Then we widen the lens further:
Why Population Medicine Is Reaching Its Limits
The Cultural Resistance to Precision Medicine
If you’re looking for a community that actually enjoys complexity— join the StayCurious Metabolism premium community. It’s for nerds who love nuance.
